Precision BioSciences to Report Third Quarter 2019 Financial Results and Present at Upcoming Investor Conferences in November
DURHAM, N.C., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that it will publish financial results for the third quarter of 2019 and provide a corporate update on November 12, 2019.
In addition, members of Precision BioSciences senior leadership will present at three investor conferences in November. Precision BioSciences CEO, Matt Kane, will also participate in a panel discussion at the Barclays Gene Editing & Gene Therapy Summit.
Barclays Gene Editing & Gene Therapy SummitDate: November 13, 2019Presentation Time: 2:45 p.m. ETPanel Time: 4:15 p.m. ETLocation: New York, NYSpeakers: Matt Kane, Chief Executive Officer
Stifel Healthcare ConferenceDate: November 20, 2019Presentation Time: 2:25 p.m. ETLocation: New York, NYSpeakers: Abid Ansari, Chief Financial Officer and Derek Jantz, PhD, Chief Scientific Officer
Jefferies London Healthcare ConferenceDate: November 20, 2019Presentation Time: 12:40 p.m. GMTLocation: London, UKSpeakers: Matt Kane, Chief Executive Officer
A live audio webcast of the Jefferies presentation will be available here ( webcast link ) and up-to-date details for each event can be found on the “Events & Presentations” page in the Investors section of the Precision BioSciences website ( www.precisionbiosciences.com ). A replay of the Jefferies presentation will also be archived for 90 days on the Events & Presentations page.
About Precision BioSciences, Inc.Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, ARCUS. Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food. For more information regarding Precision, please visit www.precisionbiosciences.com.
Investor Contact: Nick Riddle Precision BioSciences Tel. (919) 314-5512 IR@precisionbiosciences.com
Media Contact:Cory TrombleeScient Public RelationsTel. (617) 571-7220 firstname.lastname@example.org